Trial Profile
Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms Double-ITK-GVHc
- 09 Jan 2023 Primary endpoint (Response rate at 3 months (complete and partial remission) after salvage treatment with Nilotinib in patients with chronic GVHD who failed Imatinib Mesylate has not been met according to Results published in the Bone Marrow Transplantation.
- 09 Jan 2023 Results assessing Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease published in the Bone Marrow Transplantation
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.